X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stocks in this Quantisnow insightHealth Care
Historical context for XFOR
Across the 15 sessions after earlier XFOR headlines, the stock closed higher 10 times and lower 5 times, with a median move of 4.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | XFOR | SPY |
|---|---|---|---|
| May 27, 2026 | X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference | +0.8% | -0.0% |
| May 6, 2026 | X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | +4.3% | +1.4% |
| Apr 29, 2026 | X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union | -0.5% | -0.0% |
| Apr 2, 2026 | X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -2.5% | +0.1% |
| Mar 17, 2026 | X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | +18.8% | +0.3% |
| Mar 9, 2026 | Guggenheim initiated coverage on X4 Pharmaceuticals with a new price target | +10.4% | +0.9% |
Quantisnow market dataNASDAQ
XFOR
X4 Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2017
Get push alerts for XFOR
Full XFOR profile on Quantisnow Follow XFOR and get a push notification the moment its next story breaks.